XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Data (Tables)
 6 Months Ended
Jun. 29, 2018
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Reportable Segment
Selected information for the reportable segment is as follows:

Three Months Ended
 
Six Months Ended

June 29,
2018
 
June 30,
2017
 
June 29,
2018
 
June 30,
2017
Net sales:
 
 
 
 
 
 
 
Specialty Brands
$
631.7

 
$
600.1

 
$
1,204.3

 
$
1,160.1

Operating income:
 
 
 
 
 
 
 
Specialty Brands
$
265.9

 
$
270.0

 
$
506.2

 
$
537.0

Unallocated amounts:
 
 
 
 
 
 
 
Corporate and unallocated expenses (1)          
(10.2
)
 
(49.6
)
 
(53.9
)
 
(49.2
)
Intangible asset amortization
(184.3
)
 
(169.3
)
 
(360.6
)
 
(339.1
)
Restructuring and related charges, net (2)
(58.7
)
 
(1.0
)
 
(81.8
)
 
(12.3
)
Operating income
$
12.7

 
$
50.1

 
$
9.9

 
$
136.4


(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
(2)
Includes restructuring-related accelerated depreciation.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's reportable segment is as follows:
 
Three Months Ended
 
Six Months Ended
 
June 29,
2018
 
June 30,
2017
 
June 29,
2018
 
June 30,
2017
H.P. Acthar Gel
$
293.2

 
$
319.4

 
$
537.0

 
$
591.2

Inomax
131.0

 
125.5

 
270.8

 
253.9

Ofirmev
85.6

 
75.7

 
167.6

 
149.1

Therakos
56.8

 
51.2

 
114.2

 
102.4

Amitiza (1)
48.0

 
—

 
71.0

 
—

BioVectra
11.3

 
10.5

 
21.8

 
20.4

Other
5.8

 
17.8

 
21.9

 
43.1

Net sales
$
631.7

 
$
600.1

 
$
1,204.3

 
$
1,160.1


(1) Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.